Market instability expected from South Korea’s new pricing reform in 2026-2028
The drug price erosion among patent-protected drugs in South Korea may be moderate compared to other major Asia-Pacific (APAC) markets.
Pricing and Market Access
Have originator medicines’ list prices started to drop in the US?
Transformative arrival of oral weight loss medicines in the US
US comes up with two mandatory IRP use pricing models under Trump’s MFN strategy
China releases 2025 NRDL and first commercial insurance drug list
Trump administration ties pricing deals with another nine pharma companies
Second round of drug prices negotiated under the IRA revealed
Win for pharma in UK – zero US tariffs, VPAG rate cap and NICE threshold increase
